Stryker is a medical technology company with products across multiple therapeutic areas, including orthopaedics. Credit: ©BrokenSphere/Wikimedia Commons.

Stryker has acquired Israeli OrthoSpace for a total cash consideration of $220m.

The deal involves an upfront payment of $110m, followed by an additional payment of up to $110m for future milestones.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

OrthoSpace is engaged in the development and commercialisation of biodegradable balloon systems for the orthopaedic market. Its portfolio includes a technology to treat massive irreparable rotator cuff tears.

“The acquisition of OrthoSpace is highly complementary to our existing portfolio.”

OrthoSpace’s InSpace is a biodegradable sub-acromial spacer designed to realign the natural biomechanics of the shoulder. Placement of the spacer eliminates friction between two bones and reduces pain. It has received the European CE-Mark but is yet to be approved by the US Food and Drug Administration (FDA).

Stryker MedSurg group president Andy Pierce said: “The acquisition of OrthoSpace is highly complementary to our existing portfolio and aligns with Stryker’s focus on investing in sports medicine.

“We are excited about the momentum OrthoSpace has in key global markets and the additional surgical option this technology provides our customers to address a complex pathology.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Last month, the company acquired a US-based medical device company called Arrinex.

Founded in 2013, Arrinex’s portfolio consists of a new cryoablation technology ClariFix, which is indicated for treating chronic rhinitis that is known to impact more than 24 million people in the US each year.

The company started commercialising ClariFix in the US in 2017. The device extends Stryker’s Ear, Nose and Throat (ENT) portfolio.